Cargando…

International Szent-Györgyi Prize for Progress in Cancer Research: basic and translational research recognition: Mary-Claire King received the 2016 Prize for her pioneering research that demonstrated the first evidence of genetic predisposition to breast cancer

The Szent-Györgyi Prize for Progress in Cancer Research is a prestigious scientific award sponsored by the National Foundation for Cancer Research (NFCR)—a leading cancer research charitable organization in the United States that supports innovative cancer research globally with the ultimate goal to...

Descripción completa

Detalles Bibliográficos
Autores principales: Hartmann, Hali, Zhao, Jie, Ba, Sujuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697018/
https://www.ncbi.nlm.nih.gov/pubmed/29162161
http://dx.doi.org/10.1186/s40880-017-0258-8
_version_ 1783280532962934784
author Hartmann, Hali
Zhao, Jie
Ba, Sujuan
author_facet Hartmann, Hali
Zhao, Jie
Ba, Sujuan
author_sort Hartmann, Hali
collection PubMed
description The Szent-Györgyi Prize for Progress in Cancer Research is a prestigious scientific award sponsored by the National Foundation for Cancer Research (NFCR)—a leading cancer research charitable organization in the United States that supports innovative cancer research globally with the ultimate goal to cure cancer. The coveted Szent-Györgyi Prize annually honors a scientist whose seminal discovery or body of work has resulted in, or led toward, notable contributions to cancer prevention, diagnosis, or treatment; and the discovery has had a high direct impact of saving people's lives. In addition, the prize promotes public awareness of the importance of basic cancer research and encourages the sustained investment needed to accelerate the translation of these research discoveries into new cancer treatments. In 2016, NFCR’s Szent-Györgyi Prize Selection Committee was unanimous in its decision to recognize an icon in human disease genetics, Dr. Mary-Claire King, for her pioneering research that demonstrated the first evidence of genetic predisposition to breast cancer. Her proof of existence of BRCA1 gene and its location has made genetic screening for breast and ovarian cancers possible, saving lives of many people who are at high risk with inherited BRCA1 mutations.
format Online
Article
Text
id pubmed-5697018
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-56970182017-12-01 International Szent-Györgyi Prize for Progress in Cancer Research: basic and translational research recognition: Mary-Claire King received the 2016 Prize for her pioneering research that demonstrated the first evidence of genetic predisposition to breast cancer Hartmann, Hali Zhao, Jie Ba, Sujuan Chin J Cancer Editorial The Szent-Györgyi Prize for Progress in Cancer Research is a prestigious scientific award sponsored by the National Foundation for Cancer Research (NFCR)—a leading cancer research charitable organization in the United States that supports innovative cancer research globally with the ultimate goal to cure cancer. The coveted Szent-Györgyi Prize annually honors a scientist whose seminal discovery or body of work has resulted in, or led toward, notable contributions to cancer prevention, diagnosis, or treatment; and the discovery has had a high direct impact of saving people's lives. In addition, the prize promotes public awareness of the importance of basic cancer research and encourages the sustained investment needed to accelerate the translation of these research discoveries into new cancer treatments. In 2016, NFCR’s Szent-Györgyi Prize Selection Committee was unanimous in its decision to recognize an icon in human disease genetics, Dr. Mary-Claire King, for her pioneering research that demonstrated the first evidence of genetic predisposition to breast cancer. Her proof of existence of BRCA1 gene and its location has made genetic screening for breast and ovarian cancers possible, saving lives of many people who are at high risk with inherited BRCA1 mutations. BioMed Central 2017-11-21 /pmc/articles/PMC5697018/ /pubmed/29162161 http://dx.doi.org/10.1186/s40880-017-0258-8 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Editorial
Hartmann, Hali
Zhao, Jie
Ba, Sujuan
International Szent-Györgyi Prize for Progress in Cancer Research: basic and translational research recognition: Mary-Claire King received the 2016 Prize for her pioneering research that demonstrated the first evidence of genetic predisposition to breast cancer
title International Szent-Györgyi Prize for Progress in Cancer Research: basic and translational research recognition: Mary-Claire King received the 2016 Prize for her pioneering research that demonstrated the first evidence of genetic predisposition to breast cancer
title_full International Szent-Györgyi Prize for Progress in Cancer Research: basic and translational research recognition: Mary-Claire King received the 2016 Prize for her pioneering research that demonstrated the first evidence of genetic predisposition to breast cancer
title_fullStr International Szent-Györgyi Prize for Progress in Cancer Research: basic and translational research recognition: Mary-Claire King received the 2016 Prize for her pioneering research that demonstrated the first evidence of genetic predisposition to breast cancer
title_full_unstemmed International Szent-Györgyi Prize for Progress in Cancer Research: basic and translational research recognition: Mary-Claire King received the 2016 Prize for her pioneering research that demonstrated the first evidence of genetic predisposition to breast cancer
title_short International Szent-Györgyi Prize for Progress in Cancer Research: basic and translational research recognition: Mary-Claire King received the 2016 Prize for her pioneering research that demonstrated the first evidence of genetic predisposition to breast cancer
title_sort international szent-györgyi prize for progress in cancer research: basic and translational research recognition: mary-claire king received the 2016 prize for her pioneering research that demonstrated the first evidence of genetic predisposition to breast cancer
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697018/
https://www.ncbi.nlm.nih.gov/pubmed/29162161
http://dx.doi.org/10.1186/s40880-017-0258-8
work_keys_str_mv AT hartmannhali internationalszentgyorgyiprizeforprogressincancerresearchbasicandtranslationalresearchrecognitionmaryclairekingreceivedthe2016prizeforherpioneeringresearchthatdemonstratedthefirstevidenceofgeneticpredispositiontobreastcancer
AT zhaojie internationalszentgyorgyiprizeforprogressincancerresearchbasicandtranslationalresearchrecognitionmaryclairekingreceivedthe2016prizeforherpioneeringresearchthatdemonstratedthefirstevidenceofgeneticpredispositiontobreastcancer
AT basujuan internationalszentgyorgyiprizeforprogressincancerresearchbasicandtranslationalresearchrecognitionmaryclairekingreceivedthe2016prizeforherpioneeringresearchthatdemonstratedthefirstevidenceofgeneticpredispositiontobreastcancer